Pharmaceutical firms lobby to mitigate potential Trump-era drug pricing policies

Rare disease drug manufacturers are proactively lobbying to exempt their products from potential price-control measures under a prospective Trump administration. The report highlights a broader tension between GOP voter demands for healthcare fraud crackdowns and industry efforts to circumvent state-level pharmacy benefit manager (PBM) regulations.